Acrivon (ACRV) Director Palani Santhosh Receives 20,275-Share Award

What Happened

Palani Santhosh, a director of Acrivon Therapeutics, received a grant of 20,275 derivative shares on June 17, 2026. The Form 4 reports the acquisition at $0.00 (derivative award), so no immediate cash purchase or sale took place. This is a compensatory equity award rather than an open-market buy or sale.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (5 days later).
• Transaction type/code: Grant/Award (A); 20,275 derivative shares acquired at reported price $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: The shares subject to the option vest on the date immediately preceding the issuer’s next annual meeting of stockholders, subject to the reporting person’s continuous service through the applicable vesting date.
• Timeliness: Filing was submitted 5 days after the transaction (outside the typical 2-business-day window), which may indicate a late filing unless an exemption or extension applies.

Context

This was a derivative equity award (e.g., option or similar) that vests in the future rather than an immediate purchase or sale. Such grants are commonly part of director compensation and do not necessarily signal near-term buying or selling by the insider. The economic value will depend on the award terms and any future exercise/conversion.